Dymicron® is a pioneering medical technology company focused on transforming the field of musculoskeletal health. At the core of our innovation is Adymite™, a polycrystalline diamond material—one of the strongest and most wear-resistant materials known to man. Adymite is a Dymicron proprietary, patented material. Dymicron is the only company with polycrystalline diamond technology for human interbody applications.
Triadyme®-C, our flagship cervical artificial disc made with Adymite, is engineered for unmatched strength, durability, and performance in cervical total disc replacement surgery. As one of the hardest substances known to man, Adymite provides extreme durability and an ultra-low coefficient of friction. This helps Triadyme-C resist the wear, breakdown, and debris release that often limits the lifespan and safety of traditional disc replacement devices.
Ringing in the New Year
As we begin the new year, Dymicron is well-positioned for continued growth, building on the strong foundation established in 2025.
Over the past year, our focus remained on elevating global clinical awareness of Triadyme-C. This included several successful presentations at leading international spine conferences, as well as the completion of key distributor and surgeon training programs that expanded our commercial footprint worldwide.
While these accomplishments set a high standard, 2026 is shaping up to be even more transformative. We enter the year with a robust clinical roadmap, highlighted by the initiation of our U.S. FDA IDE clinical trial. By continuing to prioritize clinical excellence and data-driven innovation, we are not simply planning for a successful year, we are advancing a future in which Triadyme-C redefines expectations in disc arthroplasty surgery and elevates the benchmark for clinical outcomes.
Clinical Update
Dymicron Receives Approval and Begins the Triadyme-C IDE Clinical Trial
In July 2025. the United States Food and Drug Administration (FDA) granted Investigational Device Exemption (IDE) approval to begin a pivotal clinical study of the Triadyme–C cervical artificial disc.
This achievement marks a critical milestone in the company's mission to bring this next-generation cervical artificial disc to patients suffering from degenerative disc disease in the United States.
This month the IDE trial was intiatited with the first patient enrolled and surgery performed by Armen Khachatryan, MD at The Disc Replacement Center in South Jordan, UT. The surgery went well and the patient is doing great.
Image (from left to right): Eric Lange, Vice President, Reserch & Development, Dymicron; Armen Khachatryan, MD, Disc Replacement Center; Matt Allred, Nurse Practitioner, Disc Replacement Center.
Image: Pre-operative x-ray of disc degeneration at C3-C4 level in the cervical spine.
Image: Post-operative x-ray of Triadyme-C at C3-C4 level in the cervical spine.
Expanding Distribution
In addition to the 12 International markets where Triadyme-C is currently availabe for use, the commerical team recently added two more – the United Arab Emirates and Slovakia. Entering 2026, Triadyme-C is now commercially availabe in 14 countries worldwide.
First Paraguayan Patient Treated with cTDR
Following advanced surgeon training hosted by Armen Khachatryan, MD, in Jordan, Utah, Elio Marín, MD, returned to Paraguay and successfully performed the country’s first cervical disc arthroplasty surgery, and the first one with Dymicron’s Triadyme-C.
During the surgery, Dr. Marín performed a two-level cervical arthropasty at C5-C6 and C6-C7 and implanted two Triadyme-C artificial discs. The surgery was performed to replace two diseased discs and alleviate pain in the patient's left shoulder and arm, and numbness in the hand.
The patient, Nathalie Q., an active mom, sought a motion-preserving solution to address her symptoms while maintaining her active lifestyle. Just weeks after the procedure, she has returned to her daily activities, strength training, and once again speed skating. This successful outcome underscores the potential of cervical disc arthroplasty with Triadyme-C to restore function while preserving natural motion.
Image: Post-operative x-ray of two Triadyme-C at spinal levels at C5-C6 and C6-C7 in the cervical spine.
Image: Dr. Marín and Nathalie three days after surgery. Nathalie is the first patient in Paraguay to have a cervical disc replacement surgery.
Image: Nathalie returned to speed skating only three months after a total disc replacement with Triadyme-C.
Scaling for Success
In 2025, the commercial team partnered with, onboarded, and trained two key distributor organizations: Lifemed Group in the United Arab Emirates and Adyton in Poland, Slovakia, and the Czech Republic.
Following the trainings, both distributors secured their first Triadyme-C cases.
The commercial team plans to continue this momentum in 2026.
Image: Pictures of Lifemed Group and Adyton teams
during their training sessions.
Advancing Triadyme-C Clinical Awareness
In 2025, Triadyme-C was presented 6 times at major spinal conferences around the world. Each presentation reviewed the uniqueness of Triadyme-C and how its features translated into real clinical outcomes with the clinical data proof points. The team looks forward to continuing to building awareness and credibility about Triadyme-C's clinical benefits and success.
Questions
To contact Investor Relations, please send a message or call: Curt Ence Chief FInancial Officer Email: IR@dymicron.com
